Source comparison
Comparison: Kisspeptin Safety vs Other Reproductive Peptides
| Peptide | Mechanism | Typical Trial Duration | Most Common Adverse Events | Receptor Desensitisation Risk | Professional Assessment ||—|—|—|—|—|| Kisspeptin-54 | GPR54 agonist → GnRH release | 8–24 weeks (median 12 weeks) | Injection-site reactions, facial f
This comparison does not assign a generated winner or score.
- | Peptide | Mechanism | Typical Trial Duration | Most Common Adverse Events | Receptor Desensitisation Risk | Professional Assessment ||—|—|—|—|—|| Kisspeptin-54 | GPR54 agonist → GnRH release | 8–24 weeks (median 12 weeks) | Injection-site reactions, facial flushing | Theoretical but not observed in pulsatile human dosing | Limited long-term data; short-term safety excellent || GnRH agonists (leuprolide) | GnRH receptor agonist → initial surge, then downregulation | 12–36 months (endometriosis, fibroids) | Hot flashes, bone density loss, mood changes | Intentional mechanism (used for suppression) | Decades of long-term data; established safety profile for chronic use || hCG (human chorionic gonadotropin) | LH receptor agonist → ovulation trigger | Single-dose or 2–4 weeks (IVF cycles) | Ovarian hyperstimulation syndrome (OHSS), injection-site pain | Not applicable (short-term use) | Well-characterised; OHSS risk requires monitoring || FSH (follitropin alfa) | FSH receptor agonist → fo
- Kisspeptin sits in a unique position: it stimulates endogenous GnRH rather than replacing it or suppressing it, which theoretically preserves physiological pulsatility. GnRH agonists like leuprolide cause receptor desensitisation by design. Continuous high-dose exposure downregulates GnRH receptors in the pituitary, leading to medical castration (the intended outcome for endometriosis or prostate cancer). Kisspeptin's pulsatile dosing avoids that pathway, but whether years of exogenous pulsatile kisspeptin eventually blunts endogenous kisspeptin neuron activity is a feedback question no study has directly tested.